Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerAdnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, metastatic malignant neoplasm, neoplasm, ovarian cancer, ovarian disorder, skin disorderRecruitingPhase 1 / Phase 22026-04-01NCT05735080

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Incyclix Bio1

18 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Dana-Farber Cancer InstituteBostonUnited States626
Duke Cancer Center/ DUMCDurhamUnited States1
Emory Winship Cancer InstituteAtlantaUnited States29
Florida Cancer SpecialistsOrlandoUnited States8
Fort Wayne Medical Oncology and HematologyFort WayneUnited States22
Gabrail Cancer Research CenterCantonUnited States4
Georgia Cancer Center at Augusta UniversityAugustaUnited States23
Karmanos Cancer InstituteDetroitUnited States153
Levine Cancer Institute (LCI)- Atrium HealthCharlotteUnited States1
Mater HospitalSouth BrisbaneAustralia3
NEXT OncologyDallasUnited States4
NEXT OncologyHoustonUnited States5
Northwest Medical Specialties, PLLCTacomaUnited States29
Oncology ConsultantsHoustonUnited States22
Peninsula and South Eastern Haematology & Oncology GroupFrankstonAustralia3
Peter MacCallum Cancer CenterParkvilleAustralia3
Roswell Park Cancer InstituteBuffaloUnited States382
UTSW Medical CenterDallasUnited States1